Expanding the Scope of Geriatric Assessment for the Management of Cancer in Older Adults

Biganzoli, Laura; McCartney, Amelia; Battisti, Nicolò Matteo Luca

doi:10.1001/jamaoncol.2019.4708

Cited by 2 publications

(3 citation statements)

References 7 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study assessed FI by FI-LAB developed at the West China Hospital 25 , which was specified for patients undergoing chemotherapy for primary lung cancer. Previous studies had shown that frailty is very common in oncology patients and was associated with the development of complications, reduced OS, and increased all-cause mortality [ 2 , 11 , 12 , 14 , 25 , 28 ]. Our study also supports the identification of patients with high grade of frailty by early identification.…”

Section: Discussionmentioning

confidence: 99%

“…The probability of frailty is increasing in healthy older people over 70 years of age, over 25% in those over 85 years old [ 9 , 10 ]. Some studies had emphasized the assessment of frailty in tumor patients [ 11 , 12 ]. However, individualised treatment protocols for tumour patients based on the degree of debilitation are still being explored, geriatric assessment (GA) is the most appropriate solution to this dilemma [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

“…Some studies had emphasized the assessment of frailty in tumor patients [11,12]. However, individualised treatment protocols for tumour patients based on the degree of debilitation are still being explored, geriatric assessment (GA) is the most appropriate solution to this dilemma [11,12]. There is a growing body of research on GA assessment [7].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic significance of frailty status in patients with primary lung cancer

Wang

She

et al. 2023

BMC Geriatr

View full text Add to dashboard Cite

Lung cancer has one of the highest morbidity and mortality rates in the world. Frailty is common in many countries and is a major cause of premature functional decline and premature death in older adults, and may affect the treatment and prognosis of lung cancer patients. To investigate the predictive value of frailty at diagnosis on all-cause mortality in lung cancer patients, this study retrospectively collected and analysed clinical information on lung cancer patients from 2015–2018. A total of 1667 patients with primary lung cancer were finally included in this study. The median follow-up time of patients was 650 (493, 1001.5) days. A total of 297(17.8%) patients had FI-LAB(the frailty index based on laboratory test) status of frail at the moment of diagnosis and the all-cause mortality rate for all patients was 61.1% (1018/1667). In a univariate model, we found a higher total all-cause mortality risk in frail patients (frail vs. robust, HR(hazard ratio) = 1.616, 95% CI(confidence interval) = 1.349,1.936), after balancing other variables combined into model 1 to model 6. The results were analyzed visually using ROC(Receiver operating characteristic) curves with nomogram and the AUC values ranged from 0.866–0.874. The final inclusion of age, TNM stage, CCI(Charlson comorbidity index) score, surgery history and chemotherapy into a multifactorial model balanced the predictive power of frailty grading on all-cause mortality. The study showed that for lung cancer patients, the higher the level of frailty at diagnosis, the higher the risk of all-cause mortality. In the context of widespread electronic medical records in hospitals, it is convenient and feasible to use FI-LAB to assess the prognosis of lung cancer patients.

show abstract